Here is the design of a clinical trial:

Official Title: 4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy

Included conditions:
- Nerve Injury
- Prostate Cancer

Study Armgroups:
- {'label': 'Group A: Investigational Treatment', 'type': 'EXPERIMENTAL', 'description': '* FDA-approved 10mg dalfampridine (generic Ampyra)\n* Subjects will not take more than 2 tablets in a 24-hour period\n* Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.\n* The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.\n* Study drug can be taken with or without food.\n* If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.\n* Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine).', 'interventionNames': ['Drug: 4-Aminopyridine']}
- {'label': 'Group B: Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by a licensed compounding pharmacy. The Investigational Drug Service at Banner University Medical Center will manage the placebos.\n\nThe placebo will be tooled to look similar to the investigational treatment using Coni-Snap #00 White/White (Opaque) capsules manufactured by Medisca and CapsOral filler manufactured by Specialized Rx.', 'interventionNames': ['Other: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': '4-Aminopyridine', 'description': 'FDA-approved tablets.', 'armGroupLabels': ['Group A: Investigational Treatment'], 'otherNames': ['4-AP', 'Fampridine', 'Dalfampridine']}
- {'type': 'OTHER', 'name': 'Placebo', 'description': 'Placebo will be tooled to look similar to the study drug.', 'armGroupLabels': ['Group B: Placebo']}

Primary Outcomes:
- {'measure': 'Michigan Incontinence Sympton Index (M-ISI) (change over time)', 'description': 'Incontinence measurement (change over time)', 'timeFrame': 'Pre-operative visit, and every seven days (starting after surgery, i.e., 7 days post-op) for 6 months (up to 25 times).'}
- {'measure': 'International Index of Erectile Function (IIEF) (change over time)', 'description': 'Erectile function measurement tool. (change over time)', 'timeFrame': 'Pre-operative visit, and every seven days (starting after surgery, i.e., 7 days post-op) for 6 months (up to 25 times).'}
- {'measure': 'Placebo vs. Active Drug Questionnaire', 'description': 'Specific questions regarding patient blinding', 'timeFrame': 'through study completion, an average of 1 year'}

Please estimate the sample size based on the assumption: 
Pearson's chi-square test, 90% power, significance level of 0.05, and an estimated dropout rate of 30%.
Sample size {14}
      The primary outcome is return to baseline ability to achieve and maintain erection as measured by Item of the Abridged International Index of Erectile Function (IIEF-5) by 12Â weeks after surgery. Suppose at the conclusion of the follow-up period, the rates of returning to the baseline ability in the treatment and control groups are 70% and 30%, respectively. Pearsonâs chi-square test indicates that a sample size of 56 (with 28 individuals in each group) achieves 90% power to detect the intended difference of 40% (at a significance level of 0.05). Accounting for an estimated dropout rate of 30%, we plan to recruit 40 subjects in each group.